Mavacamten: First Approval

被引：66

作者：

Keam, Susan J. ^{[1
]}

机构：

[1] Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2022年 / 82卷 / 10期

关键词：

OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY; EXPLORER-HCM; DOUBLE-BLIND; TASK-FORCE; DIAGNOSIS; CONTRACTILITY; SENSITIVITY; MANAGEMENT; ADULTS;

D O I：

10.1007/s40265-022-01739-7

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Mavacamten (Camzyos (TM)) is an oral small-molecule cardiac myosin inhibitor developed by MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb, for the treatment of hypertrophic cardiomyopathy (HCM) and diseases of diastolic dysfunction. In April 2022, mavacamten was approved for use in the USA in the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive HCM to improve functional capacity and symptoms. This article summarizes the milestones in the development of mavacamten leading to this first approval for the treatment of adults with symptomatic NYHA class II-III obstructive HCM.

引用

页码：1127 / 1135

页数：9

共 49 条

[1]

American College of Cardiology, 2022, EFF SAF MAV TREAT OB

[2] Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers [J].

Anderson, Robert L. ;

Trivedi, Darshan V. ;

Sarkar, Saswata S. ;

Henze, Marcus ;

Ma, Weikang ;

Gong, Henry ;

Rogers, Christopher S. ;

Gorham, Joshua M. ;

Wong, Fiona L. ;

Morck, Makenna M. ;

Seidman, Jonathan G. ;

Ruppel, Kathleen M. ;

Irving, Thomas C. ;

Cooke, Roger ;

Green, Eric M. ;

Spudich, James A. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (35) :EB143-EB152

[3]

[Anonymous], 2022, Bristol Myers Squibb

[4]

[Anonymous], 2019, MYOKARDIA REG GLOB R

[5] Mavacamten decreases maximal force and Ca2+ sensitivity in the N47K-myosin regulatory light chain mouse model of hypertrophic cardiomyopathy [J].

Awinda, Peter O. ;

Watanabe, Marissa ;

Bishaw, Yemeserach ;

Huckabee, Anna M. ;

Agonias, Keinan B. ;

Kazmierczak, Katarzyna ;

Szczesna-Cordary, Danuta ;

Tanner, Bertrand C. W. .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2021, 320 (02) :H881-H890

[6] Effects of mavacamten on Ca2+sensitivity of contraction as sarcomere length varied in human myocardium [J].

Awinda, Peter O. ;

Bishaw, Yemeserach ;

Watanabe, Marissa ;

Guglin, Maya A. ;

Campbell, Kenneth S. ;

Tanner, Bertrand C. W. .

BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (24) :5609-5621

[7]

Bristol Myers Squibb, 2022, MAVACAMTEN DEMONSTRA

[8]

Bristol Myers Squibb, 2020, MYOKARDIA BRIST MYER

[9]

Bristol Myers Squibb, 2020, BRIST MYERS SQUIBB A

[10]

Bristol Myers Squibb, 2021, EUR MED AG VAL BRIST

← 1 2 3 4 5 →